



January 10, 2011

Dear Valued Customer,

In 2010, we worked with our supply partners and the FDA and continued to supply Ephedrine Sulfate Injection, USP to the hospital market. We also committed that in the fourth quarter of 2010, the current market environment would be evaluated and we would determine if there remains a need for Hospira to continue to license and manufacture this product.

We have made the difficult decision to retire Ephedrine Sulfate Injection, USP from the Hospira portfolio. We have manufactured our last production batch and anticipate that inventory will exhaust in March 2011.

Ephedrine Sulfate Injection, USP is also marketed by Akorn NDC= 17478-515-00 and Sandoz NDC = 66758-0008-02.

We apologize in advance for this inconvenience.

Thank you for your support of the Hospira Injectable Portfolio.

Kind Regards,
Jenny Gattari
Marketing Director, Specialty Pharmaceuticals